Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 1/20 | 0.69 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.66 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | MLYCD | O95822 | 1/20 | 0.51 |
| ▸ | MTOR | P42345 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6431222 | 0.82 | RXFP1 (0.71) | GRIK1RXFP1GAAKDM4EALDH1A1 | |
| SCHEMBL23864576 | 0.82 | KMT2A (0.66) | RXFP1GAAMEN1KMT2AMAPK14 | |
| SCHEMBL24713109 | 0.81 | MLYCD (0.67) | TRPV1GAAKDM4EMEN1KMT2A | |
| SCHEMBL30279458 | 0.81 | GRIK1 (0.59) | GRIK1RXFP1GAAALDH1A1MEN1 | |
| SCHEMBL22497529 | 0.81 | GRIK1 (0.59) | GRIK1RXFP1GAAALDH1A1MEN1 | |
| SCHEMBL27546747 | 0.81 | HCAR2 (0.60) | GRIK1RXFP1GAAMEN1KMT2A | |
| SCHEMBL27521543 | 0.80 | GRIK1 (0.62) | GRIK1RXFP1GAAMEN1KMT2A | |
| SCHEMBL1463217 | 0.80 | GRIK1 (1.00) | GRIK1TRPV1RXFP1KDM4EMEN1 | |
| SCHEMBL22524969 | 0.80 | GRIK1 (0.58) | GRIK1RXFP1GAAMEN1KMT2A | |
| SCHEMBL23447441 | 0.78 | MAPT (0.71) | GRIK1RXFP1GAAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-04-14 | — | — | US | claimed |
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | CPA3, HNMT, CMA1 | CFD 2266/4885GRIK1 655/4885TRPV1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.